See more : JPMorgan Indian Investment Trust plc (JII.L) Income Statement Analysis – Financial Results
Complete financial analysis of RavenQuest BioMed Inc. (RVVQF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RavenQuest BioMed Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- VIP Gloves Limited (VIP.AX) Income Statement Analysis – Financial Results
- Tingyi (Cayman Islands) Holding Corp. (TYCMY) Income Statement Analysis – Financial Results
- SPK Acquisition Corp. (SPKAU) Income Statement Analysis – Financial Results
- Taseko Mines Limited (TKO.L) Income Statement Analysis – Financial Results
- Sokensha Co.,Ltd. (7413.T) Income Statement Analysis – Financial Results
RavenQuest BioMed Inc. (RVVQF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.rqbglobal.com
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc., a cannabis company, focuses on the cannabis production, management services and consulting, and specialized research and development activities. The company operates in two segments, Consulting Business, and Cultivation and Sale of Medical Cannabis. It offers its products under the Lore Cannabis and Bloomera brand names. The company was formerly known as Ravencrest Resources Inc. and changed its name to RavenQuest BioMed Inc. in September 2017. RavenQuest BioMed Inc. was incorporated in 1987 and is based in Vancouver, Canada.
| Metric | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.26M | 112.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 455.45K | 97.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 801.29K | 14.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 63.76% | 13.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 10.24M | 634.10K | 80.12K | 79.39K | 84.04K | 100.62K | 134.05K | 110.53K | 82.12K | 91.64K | 68.28K |
| Selling & Marketing | 946.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.18M | 634.10K | 80.12K | 79.39K | 84.04K | 100.62K | 134.05K | 110.53K | 82.12K | 91.64K | 68.28K |
| Other Expenses | -10.19K | 0.00 | 0.00 | 6.60K | 1.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.98M | 656.26K | 81.46K | 76.09K | 62.34K | 105.18K | 134.05K | 110.53K | 82.12K | 91.64K | 68.28K |
| Cost & Expenses | 18.43M | 753.96K | 81.46K | 76.09K | 62.34K | 105.18K | 134.05K | 110.53K | 82.12K | 91.64K | 68.28K |
| Interest Income | 0.00 | 0.00 | 0.00 | 62.00 | 61.00 | 60.00 | 76.00 | 96.00 | 54.00 | 931.00 | 156.00 |
| Interest Expense | 1.90M | 147.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88M | 286.00 | 22.82K | 6.60K | 25.00K | 397.11K | -234.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -15.29M | -641.32K | -81.46K | -76.09K | -62.34K | 291.93K | -368.53K | -110.53K | -82.12K | -91.64K | -68.28K |
| EBITDA Ratio | -1,217.01% | -570.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.18M | -641.61K | -81.46K | -82.69K | -87.34K | -105.18K | -134.05K | -110.53K | -82.12K | -91.64K | -68.28K |
| Operating Income Ratio | -1,366.72% | -571.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.87M | -2.66M | -9.98K | 6.66K | 15.33K | -397.05K | 234.55K | 96.00 | 54.00 | 0.00 | 0.00 |
| Income Before Tax | -31.05M | -3.30M | -81.46K | -76.03K | -60.57K | -502.22K | 100.50K | -110.44K | -82.07K | 0.00 | 0.00 |
| Income Before Tax Ratio | -2,470.35% | -2,938.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -578.00K | 147.00K | -22.82K | -6.66K | -25.06K | -60.00 | -76.00 | -25.00K | 82.07K | 90.71K | 68.12K |
| Net Income | -30.47M | -3.30M | -81.46K | -76.03K | -60.57K | -502.22K | 100.50K | -85.44K | -82.07K | -90.71K | -68.12K |
| Net Income Ratio | -2,424.36% | -2,938.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.33 | -0.10 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.33 | -0.10 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 91.03M | 32.48M | 29.00M | 29.00M | 29.00M | 29.00M | 28.23M | 27.51M | 23.70M | 22.50M | 22.50M |
| Weighted Avg Shares Out (Dil) | 91.03M | 32.48M | 29.00M | 29.00M | 29.00M | 29.00M | 28.23M | 27.51M | 23.70M | 22.50M | 22.50M |
Source: https://incomestatements.info
Category: Stock Reports